SU-DHL-8 In Vitro Cellular Senescence Assay (Senescence)

This assay is to provide SU-DHL-8-based In Vitro Cellular Senescence Assay (Senescence) to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

SU-DHL-8

Human

Large Cell Lymphoma

Oncology

In Vitro Cellular Senescence Assay (Senescence)

Although numbers of various oncogenes and tumor suppressor genes have been proven to regulate senescence in normal cells, evading cellular senescence appears to be a significant step in cancer. Lysosomal senescence-associated β-galactosidase (SA-β-gal) is one of the common markers used to identify
senescent cells. Senescence-associated secretory phenotype (SASP) secretion is a characteristic of senescent cells and several cytokines (interleukins 6 and 8), proteases (stromelysin-1), growth factors (vascular endothelial growth factor [VEGF]) and ECM components are some of the examples for SASPs. During early stages, SASP components help to promote migration of effector immune cells, tissue repair and release of proteases and growth factors. p53, pRb signaling (ALDH1A3, CCNA2 and AKT1) and some cell cycle genes (CDK4, CDK6 and CDK4) have been identified as genes controlling cellular senescence.

Cellular Senescence in Cancer Assays

Cell senescence is described as an irreversible physiological event of cell growth arrest, which is known to be caused by alterations of telomeres, oxidative stress, DNA damage and some oncogenes. Inhibition of the program of senescence is one of the main features of tumor cells and it has been reported that cancer cells can be induced to undergo senescence by chemo- and radiotherapies and genetic alterations. Telomeres help to prevent uncontrolled cell proliferation and the absence of telomeres results in aneuploidy and cell death.

Cellular Senescence Assay